Bioengineering and MedTtech against cancer

Bioengineering & MedTtech against cancer   To meet the challenges in healthcare of the 21st century, it is important to combined bioengineering and MedTech to develop biological system analyze and treatment to treat specifically cancer cells and protect the rest of the patient’s body by limiting side effects. To accomplish…

Read more…

Bioengineering against cancer: IBEC researchers receive funding from La Caixa

IBEC researchers Elena Martínez, Xavier Trepat and Pere Roca-Cusachs aim to understand the processes that promote metastasis in colorectal cancer using innovative bioengineering tools, such as bioprinting and microscopy capable of revealing forces at the cellular level.

The results will be translated into a device that will recreate the tumor environment from cancer cells derived from patients, as well as a new technology that will allow to visualize how physical forces affect the nuclei of metastatic cells.

Read more…

3D printed hydrogels for cancer immunotherapy T-cell growth

The new 3D hydrogels provide high rates of cell proliferation, as they mimic lymph nodes, where T-cells reproduce in vivo. A new project, led by researchers from ICMAB and IBEC, and with the collaboration of VHIO and UIC, wants to transfer this technology to hospitals.

Cancer immunotherapy is based on using and strengthening the patient’s own immune system to recognize and fight tumor cells, without damaging healthy tissues.

Read more…

Bioengineering contributes to new advances against childhood cancer

IBEC contributes to elucidate how the rigidity of the tumor extracellular matrix affects the aggressiveness of neuroblastoma, a cancerous tumor that affects mainly children. This opens the door to generate more accurate models to predict tumor development in patients and to work in the design of new treatments.

Neuroblastoma is the most frequent malignant tumor in the first year of life. It is caused by a genetic mutation from immature nerve cells (neuroblasts) that the fetus produces as part of its development process.

Read more…

HealthTECH World Cancer day 2020

HealthTECH World Cancer day 2020 HealthTECH World Cancer day 2020 es un evento organizado en el marco del Día Mundial del Cáncer donde se darán a conocer las últimas innovaciones en materia de NANOMEDICINA contra el CÁNCER, con temas que van desde el diagnóstico precoz, la liberación controlada de fármacos…

Read more…

HealthTech World Cancer Day 2020 “Smarter technologies to beat cancer!”

IBEC-managed Spanish Nanomedicine Platform, NanoMed Spain, is co-hosteing the seventh edition of Health TECH World Cancer Day, a global initiative organized as part of World Cancer Day. It’s the fifth year running that the platform hosts the conference, which will take place next 3rd February at Sala Pau Viladiu at Hospital Duran i Reynals. Josep Samitier (Scientific Coordinator of NANOMED Spain and Director of the Institute for Bioengineering of Catalonia) and Isabel Fabregat (Coordinator of the Molecular Mechanisms and Experimental Therapy in Oncology Program and Researcher at IDIBELL) will be in charge of the opening ceremony.

Read more…

Joan Montero and colleagues in Boston suggest a new strategy for melanoma patients

IBEC researcher Joan Montero authors a paper in Nature Communications which uncovers a key adaptation that melanoma cancer cells use to evade current therapies. This finding might allow physicians to use better drug combinations to improve patient outcomes in the future.

Despite significant advances in cancer diagnosis and treatment, most targeted cancer therapies fail to achieve complete tumor regressions or durable remission. Understanding why these treatments are not always efficient has remained a main challenge for researchers and physicians. Now, Joan Montero from the IBEC and colleagues at Dana-Farber Cancer Institute/Harvard Medical School in USA report in Nature Communications a mechanism that uncovers why some therapies fail to treat melanoma.

Read more…